Author:
Poller Birk,Woessner Ralph,Barve Avantika,Tillmann Hanns-Christian,Vemula Janardhana,Nica Alexandra,Elbast Walid,Schiller Hilmar,End Peter,Camenisch Gian,Weiss Markus
Subject
Pharmacology (medical),Biochemistry, medical,Pulmonary and Respiratory Medicine
Reference29 articles.
1. Fevipiprant (QAW039), a slowly dissociating CRTh2 antagonist with the potential for improved clinical efficacy;Sykes;Mol. Pharmacol.,2016
2. Pharmacokinetics, safety, and tolerability of fevipiprant (QAW039), a novel CRTh2 receptor antagonist: results from 2 randomized, phase 1, placebo-controlled studies in healthy volunteers;Erpenbeck;Clin. Pharm. Drug Dev.,2016
3. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial;Gonem;Lancet Respir. Med.,2016
4. Asthma phenotypes: the evolution from clinical to molecular approaches;Wenzel;Nat. Med.,2012
5. The prostaglandin D2 receptor 2 pathway in asthma: a key player in airway inflammation;Domingo;Respir. Res.,2018
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献